In a bold step to accelerate pharmaceutical manufacturing, the Uttar Pradesh State Industrial Development Authority (UPSIDA) has announced the release of 100 industrial plots in Lalitpur, aiming to attract pharma companies to the Bundelkhand region. This strategic initiative is part of the state’s broader mission to expand its footprint in the life sciences sector and contribute to India’s ambition of becoming a global pharmaceutical hub.
The plots, ranging in size from 2,100 to 10,500 square meters, are located in the Plastic City Industrial Area of Lalitpur, near the Uttar Pradesh-Madhya Pradesh border. The site has been strategically selected to capitalize on regional connectivity and upcoming infrastructure development.
Incentives and Strategic Advantage
Companies establishing manufacturing units in Lalitpur will benefit from a combination of government incentives, infrastructure support, and access to emerging logistics corridors. UPSIDA highlighted the area’s competitive land pricing, robust connectivity, and supportive policy environment as key advantages for investors seeking new project sites or expansion opportunities.
Strengthening India’s Pharma Supply Chain
With India’s pharmaceutical exports surpassing $25 billion, the development of regional manufacturing clusters like Lalitpur is crucial to meeting future global demand, creating employment, and reducing reliance on imported bulk drugs. The initiative is also expected to bolster supply chain resilience and encourage backward integration in the sector.
UPSIDA has called on pharma companies to act swiftly, as the allocation of these plots is limited and demand is expected to be high.